4
44M
4
3
- Areas of investment
Summary
Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight iSTAR Medical, Xeltis. The fund has specific favorite in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the LSP, startups are often financed by VI Partners AG, Life Sciences Partners, Kurma Partners. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Gimv.
The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 3
- Investments by industry
- Health Care (3)
- Medical Device (3)
- Therapeutics (3)
- Manufacturing (1)
- Biotechnology (1) Show 1 more
- Investments by region
-
- Belgium (2)
- France (1)
- Switzerland (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 0.75
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Amolyt Pharma | 31 Jul 2019 | Health Care, Medical, Therapeutics | Early Stage Venture | 79M | Rhone-Alpes, Écully, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.